Consumers who bought certain prescription generics between May 1, 2009, and Dec. 31, 2019, have until Nov. 9, 2026, to file a claim in a price-fixing settlement covering 197 named drugs. The deadline applies to two settlements, with Sandoz and with Sun and Taro, inside a federal antitrust case accusing dozens of generic drugmakers of coordinating prices. Payment is not automatic: it starts only after a claim form and proof of purchase reach the administrator.
Notice dates and filing steps for the generic-drug claim. The Settlement & Refund Recovery System includes the four-date rule for reading a settlement notice and a step-by-step filing walkthrough.
Get the notice-reading rule and filing walkthrough for this claim →
Two class settlements, 197 drugs and a 2009 to 2019 window
The official claim form identifies the Sandoz Settlement Class and the Sun/Taro Settlement Class in case number 2:16-MD-02724, the multidistrict litigation over generic drug pricing. Its Appendix A lists 197 distinct generic medications, and only purchases made from May 1, 2009, through Dec. 31, 2019, fall inside the class period. A submission must be filed online, or mailed and postmarked, no later than Nov. 9, 2026, which is 40 days after this article’s date.
The class is broad in geography. The form covers all persons and entities in the 50 states except Indiana and Ohio, along with the District of Columbia, Puerto Rico and the U.S. Virgin Islands. The settlement-tracking site OpenClassActions, which is not a court or an agency, describes the eligible group as end payers: consumers who paid for the drugs, plus health insurers, employer plans and union benefit plans that reimbursed the cost.
The underlying allegation is bid rigging by the makers themselves. According to a Legal Examiner report published Aug. 21, 2026, generic drug executives divided up which company would offer the lowest price to a given pharmacy or distributor, while competitors submitted deliberately higher bids to create the look of competition. The same report says the Justice Department charged four senior executives and seven generic drug companies, and that three of the executives pleaded guilty.
Drug names matter because eligibility is drug-specific, not brand-specific. The Legal Examiner report lists pravastatin, carbamazepine and tobramycin among the medications in the litigation, along with dermatological products such as clobetasol, clotrimazole, desonide and fluocinonide, and it names Sandoz, its former parent Novartis, Heritage, Sun and Taro, Apotex, Glenmark, Lannett and Bausch among the companies involved. The complete list of covered products sits in Appendix A of the claim form, and a purchase of an unlisted generic does not count.
The claim form leaves the fund total and the payment date unstated
The claim form does not disclose how large the settlement funds are or what an individual claimant might receive. Trackers fill that gap unevenly. OpenClassActions lists a $275 million Sandoz and Fougera end-payer settlement and a $200 million Sun and Taro end-payer settlement, while the Legal Examiner report describes the Sandoz resolution as $450 million, made up of $400 million paid over seven years and $50 million for states. Those figures cover different scopes, so no single fund total is stated here.
Court approval dates are clearer. The tracker records final approval of the Sandoz settlement on Sept. 26, 2025, and of the Sun and Taro settlement on Jan. 23, 2026. Approval settles whether the deal stands, but neither the claim form nor the tracker gives a date on which checks or deposits will go out, and the amount per claimant will depend on how many valid claims arrive before the Nov. 9 cutoff. That unresolved timing is the main open question for anyone filing now.
A second track exists for consumers, run by state attorneys general. Legal Examiner points to a separate registration site, aggenericdrugs.com, and OpenClassActions lists a State AG consumer claim deadline of March 8, 2027. That program has its own process and its own date, so a claim filed through the administrator’s site for the Sandoz and Sun/Taro classes does not appear to be the same filing. Readers who bought in Indiana or Ohio are the group most likely to need to look at that second track.
Receipts from 2009 onward, Appendix A matching and three exclusions
The form asks for proof that a purchase happened inside the class period. Accepted records are receipts or invoices, account statements, an itemized record of purchases, or other records that show a purchase between May 1, 2009, and Dec. 31, 2019. The Legal Examiner report describes the requirement as a receipt or pharmacy records. Each purchase also has to be a drug from the 197-name Appendix A, so a claimant needs the exact medication name for every fill listed.
Three groups are shut out of the class by the form itself. Medicaid-covered consumers are excluded, along with defendants’ officers and employees, judges, purchasers who bought for resale, and anyone who opted out. Indiana and Ohio are carved out of the 50-state class, which means a purchase made in either state does not qualify under this form. Payments can be requested by ACH direct deposit, Zelle, PayPal, Venmo or paper check, so the form also asks each claimant to choose a route.
Filing costs nothing and runs through the administrator’s own site, GenericDrugsEndPayerSettlement.com, where the claim can be filed online, or by mail to A.B. Data, Ltd., P.O. Box 173118, Milwaukee, WI 53217, postmarked by Nov. 9, 2026. Questions go to the administrator’s toll-free line at 1-877-316-0171, and the claim form does not describe any fee for filing.
Open class-action settlements listed in one place
The generic-drug claim is one of many open class-action settlements, each with its own deadline, claim form and proof requirement. MoneyPilot lists open class-action settlements and shows which ones may match a member, then files claim forms for members and tracks deadlines and payout status. MoneyPilot is a paid subscription service.
Look up open settlements MoneyPilot matches before the Nov. 9 claim deadline → We may earn a commission if you buy through this link.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.